


Intelligent Fingerprinting (“IFP”) is a UK medical diagnostic company with a unique screening technology for the detection of drugs of abuse using the sweat of a fingerprint. The IFP platform uses proprietary lateral flow technology and customized imaging detection hardware and has 16 patent families (10 published; 4 granted). IFP operates globally from an 11,000 sq. ft. facility in Cambridge, UK and employs 30 people. IFP is led by drug testing industry expert Philip Hand, co-founder of Cozart PLC, a pioneering developer of oral fluid drug testing, and is supported by Emeritus Professor David Russell, Founder of IFP, and a team of 4 senior diagnostics and industry specialists.



Non-invasive, dignified, 50 second sample collection; Results within minutes

Key Investment Highlights

- ◆ IFP generated £507K revenue in 2019; rising to £2.5M in 2020
- ◆ Positive EBITDA at £4.3M in revenue (2021); Low-cost hand-held reader ready in early 2020
- ◆ \$3.5B worldwide market testing for drugs of abuse
- ◆ Proprietary platform uniquely suited for medical diagnostic applications

Capital Structure, Investment Security and Use of Funds

IFP has no debt; prior capital is all common stock ◆ Subscription for ‘A’ Ordinary shares ◆ Capital will be used to fund targeted sales growth, new assay development, regulatory approvals and manufacturing scale up.

Company Strengths

- The only provider of fingerprint testing for drugs of abuse worldwide (safe, non-invasive, and dignified)
- New portable instrumentation development is underway; Completion early 2020
- Significant market potential: Intelligent Fingerprinting’s technology is primarily aimed at the worldwide Drugs of Abuse testing market with a forecast value of \$3.55Bn in 2020 and a CAGR of 4.5% (source: BCC Research LLC)
- Highly scalable technology operation; Focused on “razor/razorblade” model with high gross margin consumable
- Further developments into diverse areas of medical diagnostics are planned; This will access the Global Point of Care market with a forecast value of \$31.3Bn and a CAGR of 10% (source: markets & markets.com)
- Filed for FDA approval for use in the US workplace market. Currently available for forensic, drug rehab, and monitoring use in the US.

Uses for Current IFP Drug Screening Products

Law Enforcement/Public Safety— roadside screening and other law enforcement uses.

Criminal Justice/Department of Corrections—screening for probation, parole, and prisons

Drug Rehabilitation—screening to monitor and support treatment programs.

Medical Examiners/Coroners—establish cause of death without full post mortem

Workplace/Employment* Screening—random workplace or pre-employment screening

* Workplace/Employment screening in US requires FDA approval. Application to FDA submitted, but final approval not anticipated until 2020. Products are currently available in US for forensic, drug rehab, and monitoring use.

Current Available Product Set

Version 1 Criminal Justice		Version 2 Drug Treatment	
- Opiates	- Methamphetamine	- Opiates	- Methadone
- Cocaine	- Cannabis	- Benzodiazepines	- Buprenorphine

Other Potential Products

Version for Opioid Addiction		Versions for Medical Diagnostics	
- Oxycodone	- Fentanyl	- Fertility and pregnancy	
- Heroin marker (6-AM)	- Phencyclidine	- Medical screening for disease markers	
		- Compliance with drug treatment protocols	

Intelligent Fingerprinting World Representation



Contact

Philip Hand—Executive Chairman
 E: Philip.Hand@intelligentfingerprinting.com
 T: +44 (0)1223 941941
 M: +44 (0)7970 698334